lpv lopinavir Search Results


86
Japan Energy Corporation lopinavir lpv
Lopinavir Lpv, supplied by Japan Energy Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lopinavir lpv/product/Japan Energy Corporation
Average 86 stars, based on 1 article reviews
lopinavir lpv - by Bioz Stars, 2025-02
86/100 stars
  Buy from Supplier

86
CEM Corporation lopinavir lpv
Effects of (a) pre-incubating CEM, CEME1000 (E1000) and CEMVBL (VBL) cells with various concentrations (0–30 µM) of unlabelled <t>lopinavir</t> <t>(LPV)</t> followed by the addition of [14C]LPV and (b) co-incubating the cells with [14C]LPV followed by the addition of various concentrations (0–30 µM) of unlabelled LPV on the accumulation of [14C]LPV. Bars indicate mean ± SD (n = 4, with four independent observations from cultured CEM and its variant cells). Results are expressed as the CAR, being the ratio of the amount of [14C]LPV associated with the cell pellets to the amount in a similar volume of medium after incubation. P values of *P < 0.05, **P < 0.01 and ***P < 0.001 indicate statistically significant differences in the CAR of [14C]LPV between control and drug-treated samples.
Lopinavir Lpv, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lopinavir lpv/product/CEM Corporation
Average 86 stars, based on 1 article reviews
lopinavir lpv - by Bioz Stars, 2025-02
86/100 stars
  Buy from Supplier

86
Abbott Laboratories lopinavir lpv
Effects of (a) pre-incubating CEM, CEME1000 (E1000) and CEMVBL (VBL) cells with various concentrations (0–30 µM) of unlabelled <t>lopinavir</t> <t>(LPV)</t> followed by the addition of [14C]LPV and (b) co-incubating the cells with [14C]LPV followed by the addition of various concentrations (0–30 µM) of unlabelled LPV on the accumulation of [14C]LPV. Bars indicate mean ± SD (n = 4, with four independent observations from cultured CEM and its variant cells). Results are expressed as the CAR, being the ratio of the amount of [14C]LPV associated with the cell pellets to the amount in a similar volume of medium after incubation. P values of *P < 0.05, **P < 0.01 and ***P < 0.001 indicate statistically significant differences in the CAR of [14C]LPV between control and drug-treated samples.
Lopinavir Lpv, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lopinavir lpv/product/Abbott Laboratories
Average 86 stars, based on 1 article reviews
lopinavir lpv - by Bioz Stars, 2025-02
86/100 stars
  Buy from Supplier

86
AbbVie Inc lopinavir lpv
Agreements for ARV medicines with the MPP.
Lopinavir Lpv, supplied by AbbVie Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lopinavir lpv/product/AbbVie Inc
Average 86 stars, based on 1 article reviews
lopinavir lpv - by Bioz Stars, 2025-02
86/100 stars
  Buy from Supplier

Image Search Results


Effects of (a) pre-incubating CEM, CEME1000 (E1000) and CEMVBL (VBL) cells with various concentrations (0–30 µM) of unlabelled lopinavir (LPV) followed by the addition of [14C]LPV and (b) co-incubating the cells with [14C]LPV followed by the addition of various concentrations (0–30 µM) of unlabelled LPV on the accumulation of [14C]LPV. Bars indicate mean ± SD (n = 4, with four independent observations from cultured CEM and its variant cells). Results are expressed as the CAR, being the ratio of the amount of [14C]LPV associated with the cell pellets to the amount in a similar volume of medium after incubation. P values of *P < 0.05, **P < 0.01 and ***P < 0.001 indicate statistically significant differences in the CAR of [14C]LPV between control and drug-treated samples.

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes

doi: 10.1093/jac/dkq082

Figure Lengend Snippet: Effects of (a) pre-incubating CEM, CEME1000 (E1000) and CEMVBL (VBL) cells with various concentrations (0–30 µM) of unlabelled lopinavir (LPV) followed by the addition of [14C]LPV and (b) co-incubating the cells with [14C]LPV followed by the addition of various concentrations (0–30 µM) of unlabelled LPV on the accumulation of [14C]LPV. Bars indicate mean ± SD (n = 4, with four independent observations from cultured CEM and its variant cells). Results are expressed as the CAR, being the ratio of the amount of [14C]LPV associated with the cell pellets to the amount in a similar volume of medium after incubation. P values of *P < 0.05, **P < 0.01 and ***P < 0.001 indicate statistically significant differences in the CAR of [14C]LPV between control and drug-treated samples.

Article Snippet: We also observed that in PBMCs there was a significant increase ( P < 0.001) in the CAR of [ 14 C]lopinavir) in a concentration-dependent fashion (Figure ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 1 caption a7 Effects of (a) pre-incubating CEM, CEM E1000 (E1000) and CEM VBL (VBL) cells with various concentrations (0–30 µM) of unlabelled lopinavir (LPV) followed by the addition of [ 14 C]LPV and (b) co-incubating the cells with [ 14 C]LPV followed by the addition of various concentrations (0–30 µM) of unlabelled LPV on the accumulation of [ 14 C]LPV.

Techniques: Cell Culture, Variant Assay, Incubation

Effects of (a) pre-incubating CEM, CEME1000 (E1000) and CEMVBL (VBL) cells with fixed concentrations (30 µM) of unlabelled lopinavir (LPV) (alone and in combination with 1 µM tariquidar or 50 µM MK571), (b) co-incubating the PBMCs with 10 and 30 µM unlabelled LPV (alone and in combination with 1 µM tariquidar or 50 µM frusemide) on the accumulation of [14C]LPV, (c) pre-incubating CEM, E1000 and VBL cells with various concentrations (0–30 µM) of unlabelled LPV followed by the addition of [3H]saquinavir (SQV) and (d) pre-incubating CEM, VBL and E1000 cells with various concentrations (0–30 µM) of unlabelled LPV on the accumulation of [3H] ritonavir (RTV). Bars indicate mean ± SD (n = 4, with four independent observations from cultured CEM and its variant cells and n = 4 with four independent observations from each buffy coat PBMC sample). P values of *P < 0.05, **P < 0.01 and ***P < 0.001 indicate statistically significant differences in the CAR of [14C]LPV or [3H]SQV between controls and drug-treated samples. Note that tariquidar/LPV combinations were compared with samples treated with tariquidar alone.

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes

doi: 10.1093/jac/dkq082

Figure Lengend Snippet: Effects of (a) pre-incubating CEM, CEME1000 (E1000) and CEMVBL (VBL) cells with fixed concentrations (30 µM) of unlabelled lopinavir (LPV) (alone and in combination with 1 µM tariquidar or 50 µM MK571), (b) co-incubating the PBMCs with 10 and 30 µM unlabelled LPV (alone and in combination with 1 µM tariquidar or 50 µM frusemide) on the accumulation of [14C]LPV, (c) pre-incubating CEM, E1000 and VBL cells with various concentrations (0–30 µM) of unlabelled LPV followed by the addition of [3H]saquinavir (SQV) and (d) pre-incubating CEM, VBL and E1000 cells with various concentrations (0–30 µM) of unlabelled LPV on the accumulation of [3H] ritonavir (RTV). Bars indicate mean ± SD (n = 4, with four independent observations from cultured CEM and its variant cells and n = 4 with four independent observations from each buffy coat PBMC sample). P values of *P < 0.05, **P < 0.01 and ***P < 0.001 indicate statistically significant differences in the CAR of [14C]LPV or [3H]SQV between controls and drug-treated samples. Note that tariquidar/LPV combinations were compared with samples treated with tariquidar alone.

Article Snippet: We also observed that in PBMCs there was a significant increase ( P < 0.001) in the CAR of [ 14 C]lopinavir) in a concentration-dependent fashion (Figure ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 1 caption a7 Effects of (a) pre-incubating CEM, CEM E1000 (E1000) and CEM VBL (VBL) cells with various concentrations (0–30 µM) of unlabelled lopinavir (LPV) followed by the addition of [ 14 C]LPV and (b) co-incubating the cells with [ 14 C]LPV followed by the addition of various concentrations (0–30 µM) of unlabelled LPV on the accumulation of [ 14 C]LPV.

Techniques: Cell Culture, Variant Assay

Effects of pre-incubating PBMCs with various concentrations (0–30 µM) of unlabelled lopinavir (LPV) followed by the addition of [14C]LPV and co-incubating the cells with [14C]LPV followed by various concentrations (0–30 µM) of unlabelled LPV (trans-stimulation) on the accumulation of [14C]LPV. Bars indicate mean ± SD (n = 6, with four independent observations from each buffy coat PBMC sample). P values of *P < 0.05, **P < 0.01 and ***P < 0.001 indicate statistically significant differences in the CAR of [14C]LPV between control and LPV-treated samples.

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes

doi: 10.1093/jac/dkq082

Figure Lengend Snippet: Effects of pre-incubating PBMCs with various concentrations (0–30 µM) of unlabelled lopinavir (LPV) followed by the addition of [14C]LPV and co-incubating the cells with [14C]LPV followed by various concentrations (0–30 µM) of unlabelled LPV (trans-stimulation) on the accumulation of [14C]LPV. Bars indicate mean ± SD (n = 6, with four independent observations from each buffy coat PBMC sample). P values of *P < 0.05, **P < 0.01 and ***P < 0.001 indicate statistically significant differences in the CAR of [14C]LPV between control and LPV-treated samples.

Article Snippet: We also observed that in PBMCs there was a significant increase ( P < 0.001) in the CAR of [ 14 C]lopinavir) in a concentration-dependent fashion (Figure ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 1 caption a7 Effects of (a) pre-incubating CEM, CEM E1000 (E1000) and CEM VBL (VBL) cells with various concentrations (0–30 µM) of unlabelled lopinavir (LPV) followed by the addition of [ 14 C]LPV and (b) co-incubating the cells with [ 14 C]LPV followed by the addition of various concentrations (0–30 µM) of unlabelled LPV on the accumulation of [ 14 C]LPV.

Techniques:

Agreements for ARV medicines with the MPP.

Journal: PLoS ONE

Article Title: Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP)

doi: 10.1371/journal.pone.0177770

Figure Lengend Snippet: Agreements for ARV medicines with the MPP.

Article Snippet: Lopinavir (LPV) , AbbVie Inc , First line for paediatrics and second-line for adults and paediatrics , Nov-14 Dec-15 , 2026 , 2.

Techniques: Infection